Market Overview

UPDATE: Jefferies Raises PT to $29 on Aegerion Pharmaceuticals on Juxtapid Approval Outlook

Related AEGR
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
Aegerion Pharmaceuticals Announces Resolution Of Warning Letter for JUXTAPID (lomitapide) Capsules

Jefferies reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) and raised its price target from $24 to $29.

Jefferies commented, "Juxtapid (lomitapide) approval for HoFH is in-line (EU decision in mid-2013). AEGR is to provide details on its commercial plan (# of identified pts, WAC, etc) on Jan 7-10. Key to commercial success of Juxtapid is # of eligible pts; AEGR maintains ~3K U.S. pts. For FY13, our Juxtapid sales estimate is $13M (on FY basis, 40-60 treated pts on AEGR pricing range; vs. cons. $24M). Increasing our probabilityadjusted PT upon approval."

Aegerion Pharmaceuticals closed at $24.46 on Wednesday.

Latest Ratings for AEGR

Aug 2014Deutsche BankMaintainsBuy
May 2014Goldman SachsInitiates Coverage onSell
May 2014Cowen & CompanyDowngradesOutperformMarket Perform

View More Analyst Ratings for AEGR
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (AEGR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters